Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies
BackgroundTo evaluate the impact of time to castration resistance (TTCR) in metastatic hormone-sensitive prostate cancer (mHSPC) patients on overall survival (OS) in the era of combination therapies for mHSPC.Material and MethodsOf 213 mHSPC patients diagnosed between 01/2013-12/2020 who subsequentl...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.659135/full |
id |
doaj-b617ad5a712a4892be499fc43d328766 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Mike Wenzel Mike Wenzel Felix Preisser Benedikt Hoeh Maria Schroeder Christoph Würnschimmel Christoph Würnschimmel Thomas Steuber Hans Heinzer Severine Banek Marit Ahrens Andreas Becker Pierre I. Karakiewicz Felix K. H. Chun Luis A. Kluth Philipp Mandel |
spellingShingle |
Mike Wenzel Mike Wenzel Felix Preisser Benedikt Hoeh Maria Schroeder Christoph Würnschimmel Christoph Würnschimmel Thomas Steuber Hans Heinzer Severine Banek Marit Ahrens Andreas Becker Pierre I. Karakiewicz Felix K. H. Chun Luis A. Kluth Philipp Mandel Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies Frontiers in Oncology mortality survival castration resistance metastatic prostate cancer CRPC |
author_facet |
Mike Wenzel Mike Wenzel Felix Preisser Benedikt Hoeh Maria Schroeder Christoph Würnschimmel Christoph Würnschimmel Thomas Steuber Hans Heinzer Severine Banek Marit Ahrens Andreas Becker Pierre I. Karakiewicz Felix K. H. Chun Luis A. Kluth Philipp Mandel |
author_sort |
Mike Wenzel |
title |
Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies |
title_short |
Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies |
title_full |
Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies |
title_fullStr |
Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies |
title_full_unstemmed |
Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies |
title_sort |
impact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-04-01 |
description |
BackgroundTo evaluate the impact of time to castration resistance (TTCR) in metastatic hormone-sensitive prostate cancer (mHSPC) patients on overall survival (OS) in the era of combination therapies for mHSPC.Material and MethodsOf 213 mHSPC patients diagnosed between 01/2013-12/2020 who subsequently developed metastatic castration resistant prostate cancer (mCRPC), 204 eligible patients were analyzed after having applied exclusion criteria. mHSPC patients were classified into TTCR <12, 12-18, 18-24, and >24 months and analyzed regarding OS. Moreover, further OS analyses were performed after having developed mCRPC status according to TTCR. Logistic regression models predicted the value of TTCR on OS.ResultsMedian follow-up was 34 months. Among 204 mHSPC patients, 41.2% harbored TTCR <12 months, 18.1% for 12-18 months, 15.2% for 18-24 months, and 25.5% for >24 months. Median age was 67 years and median PSA at prostate cancer diagnosis was 61 ng/ml. No differences in patient characteristics were observed (all p>0.05). According to OS, TTCR <12 months patients had the worst OS, followed by TTCR 12-18 months, 18-24 months, and >24 months, in that order (p<0.001). After multivariable adjustment, a 4.07-, 3.31-, and 6.40-fold higher mortality was observed for TTCR 18-24 months, 12-18 months, and <12 months patients, relative to TTCR >24 months (all p<0.05). Conversely, OS after development of mCRPC was not influenced by TTCR stratification (all p>0.05).ConclusionPatients with TTCR <12 months are at the highest OS disadvantage in mHSPC. This OS disadvantage persisted even after multivariable adjustment. Interestingly, TTCR stratified analyses did not influence OS in mCRPC patients. |
topic |
mortality survival castration resistance metastatic prostate cancer CRPC |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.659135/full |
work_keys_str_mv |
AT mikewenzel impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT mikewenzel impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT felixpreisser impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT benedikthoeh impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT mariaschroeder impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT christophwurnschimmel impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT christophwurnschimmel impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT thomassteuber impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT hansheinzer impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT severinebanek impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT maritahrens impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT andreasbecker impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT pierreikarakiewicz impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT felixkhchun impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT luisakluth impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies AT philippmandel impactoftimetocastrationresistanceonsurvivalinmetastatichormonesensitiveprostatecancerpatientsintheeraofcombinationtherapies |
_version_ |
1721512917160951808 |
spelling |
doaj-b617ad5a712a4892be499fc43d3287662021-04-23T08:37:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-04-011110.3389/fonc.2021.659135659135Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination TherapiesMike Wenzel0Mike Wenzel1Felix Preisser2Benedikt Hoeh3Maria Schroeder4Christoph Würnschimmel5Christoph Würnschimmel6Thomas Steuber7Hans Heinzer8Severine Banek9Marit Ahrens10Andreas Becker11Pierre I. Karakiewicz12Felix K. H. Chun13Luis A. Kluth14Philipp Mandel15Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, GermanyCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, CanadaDepartment of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, GermanyDepartment of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, GermanyDepartment of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, GermanyCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, CanadaMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, GermanyMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, GermanyMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, GermanyDepartment of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, GermanyDepartment of Hematology and Oncology, University Hospital Frankfurt, Frankfurt, GermanyDepartment of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, GermanyCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC, CanadaDepartment of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, GermanyDepartment of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, GermanyDepartment of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, GermanyBackgroundTo evaluate the impact of time to castration resistance (TTCR) in metastatic hormone-sensitive prostate cancer (mHSPC) patients on overall survival (OS) in the era of combination therapies for mHSPC.Material and MethodsOf 213 mHSPC patients diagnosed between 01/2013-12/2020 who subsequently developed metastatic castration resistant prostate cancer (mCRPC), 204 eligible patients were analyzed after having applied exclusion criteria. mHSPC patients were classified into TTCR <12, 12-18, 18-24, and >24 months and analyzed regarding OS. Moreover, further OS analyses were performed after having developed mCRPC status according to TTCR. Logistic regression models predicted the value of TTCR on OS.ResultsMedian follow-up was 34 months. Among 204 mHSPC patients, 41.2% harbored TTCR <12 months, 18.1% for 12-18 months, 15.2% for 18-24 months, and 25.5% for >24 months. Median age was 67 years and median PSA at prostate cancer diagnosis was 61 ng/ml. No differences in patient characteristics were observed (all p>0.05). According to OS, TTCR <12 months patients had the worst OS, followed by TTCR 12-18 months, 18-24 months, and >24 months, in that order (p<0.001). After multivariable adjustment, a 4.07-, 3.31-, and 6.40-fold higher mortality was observed for TTCR 18-24 months, 12-18 months, and <12 months patients, relative to TTCR >24 months (all p<0.05). Conversely, OS after development of mCRPC was not influenced by TTCR stratification (all p>0.05).ConclusionPatients with TTCR <12 months are at the highest OS disadvantage in mHSPC. This OS disadvantage persisted even after multivariable adjustment. Interestingly, TTCR stratified analyses did not influence OS in mCRPC patients.https://www.frontiersin.org/articles/10.3389/fonc.2021.659135/fullmortalitysurvivalcastration resistancemetastatic prostate cancerCRPC |